Seeking Alpha

Teva (TEVA) is facing a bill of up to $2.1B for selling generic versions of Pfizer's (PFE)...

Teva (TEVA) is facing a bill of up to $2.1B for selling generic versions of Pfizer's (PFE) heartburn drug Protonix before its U.S. patent exclusivity expired in 2011. Teva had already provisioned $670M in Q3 and said this week that the figure could go up by another $1.4B. A trial for Pfizer's claim for damages is due to start in June, while Teva also plans to appeal a jury verdict that upheld Protonix's patent.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)